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Abstract
Introduction Optical coherence tomography (OCT) enables detailed imaging of the coronary wall, lumen and intracoronary
implanted devices. Responding to the lack of specific appropriate use criteria (AUC) for this technique, we conducted
a literature review and a procedure for appropriate use criteria.
Methods Twenty-one of all 184 members of the Dutch Working Group on Interventional Cardiology agreed to evaluate
49 pre-specified cases. During a meeting, factual indications were established whereupon members individually rated
indications on a 9-point scale, with the opportunity to substantiate their scoring.
Results Twenty-six indications were rated ‘Appropriate’, eighteen indications ‘May be appropriate’, and five ‘Rarely
appropriate’. Use of OCT was unanimously considered ‘Appropriate’ in stent thrombosis, and ‘Appropriate’ for guidance
in PCI, especially in distal left main coronary artery and proximal left anterior descending coronary artery, unexplained
angiographic abnormalities, and use of bioresorbable vascular scaffold (BVS). OCT was considered ‘Rarely Appropriate’
on top of fractional flow reserve (FFR) for treatment indication, assessment of strut coverage, bypass anastomoses or
assessment of proximal left main coronary artery.
Conclusions The use of OCT in stent thrombosis is unanimously considered ‘Appropriate’ by these experts. Varying
degrees of consensus exists on the appropriate use of OCT in other settings.
Keywords Coronary artery disease · PCI · OCT
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Introduction
Intracoronary optical coherence tomography (OCT) is
a catheter-based, high-resolution imaging technique using
backscattering of near-infrared light for the characterisation
of the coronary artery wall, plaque morphology/pathology
and intracoronary devices such as stents [1–3].
Compared with intravascular ultrasound (IVUS), OCT
images are acquired faster and the axial resolution is higher
[1–3]. IVUS has a larger penetration depth of 4–8mm ver-
sus 0.1–2mm for OCT, depending on the variable atten-
uation of near infrared light by various tissue types [1–3].
Because of its detail in visualisation of plaque composition,
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Table 1 Formation Dutch working group on optical coherence
tomography
Number of del-
egates/centre
(N = 21)
Participating hospital
1 Amsterdam Medical Centre, Amsterdam
3 Amphia Hospital, Breda
1 Albert Schweitzer Hospital, Dordrecht
2 Erasmus Medical Centre, Rotterdam
1 Leiden University Medical Centre, Leiden
1 MC Haaglanden, the Hague
2 Northwest Clinics; Alkmaar
3 Radboud University Medical Centre, Ni-
jmegen
3 St Antonius Hospital, Nieuwegein
2 University Medical Centre Groningen,
Groningen
1 University Medical Centre Utrecht, Utrecht
1 VU University Medical Centre, Amsterdam
Table 2 Fixed format of clinical scenariosa
1 Clinical presentation
2 Risk factors and comorbidities
3 Cardiac history
4 Non-invasive tests results to evaluate the presence and
severity of myocardial ischaemia; electrocardiography,
laboratory and non-invasive ischaemia detection
5 Formal coronary angiography reports
6 Invasive testing such as intravascular ultrasound and frac-
tional flow reserve
aAll submitted scenarios for the use of optical coherence tomography
were developed according to a fixed format considering all the above
mentioned common variables
dissection, thrombus and stents, OCT is increasingly used
during coronary angiography and PCI.
The wealth of information that is gained with this tech-
nique needs to be placed in a clinical perspective. Although
several expert groups have formulated standards on acqui-
sition, measurements, terminology and clinical applications
of OCT [1–3], evaluation according to an analysis of appro-
priate use criteria in combination with a literature review
is lacking. This document aims to provide a framework for
the appropriate use of OCT in daily clinical practice.
Methods
This document covers a range of scenarios representing
everyday clinical practice.
Twenty-one of all 184 members of the Dutch Working
Group on Interventional Cardiology responded positively
to creating a consensus panel (Tab. 1), forming a repre-
sentative reflection of the thirty Dutch cardiovascular in-
tervention clinics. Panellists were asked to submit clinical
scenarios as encountered within their own practice, accord-
ing to a fixed format (Tab. 2). Scenarios were categorised
by indication, and reviewed until consensus on factual in-
dications was reached.
Appropriate use criteria
Use of OCT was defined appropriate when ‘potential bene-
fits, in terms of health outcomes (survival, symptoms, func-
tional status, and/or quality of life), exceed negative conse-
quences of the treatment strategy’ [4].
Scenarios were scored on a 1–9 scale:
Scores 7–9: Appropriate; OCT likely improves health
outcomes.
Scores 4–6: May be appropriate; Uncertainty that OCT
improves health outcomes.
Scores 1–3: Rarely appropriate; Unlikely that OCT im-
proves health outcomes.
According to prescribed assumptions (Tab. 3; [5]), pan-
ellists anonymously scored scenarios.
Statistics
Scores were categorised according to the appropriate use
criteria scale [4]. Overall scores of each indication for OCT
were described descriptively as mean± SD. Outliers were
defined as observations 1.5 times the interquartile range
above the third quartile or below the first quartile.
Results
Twenty-one cardiologists rated 49 submitted OCT scenar-
ios (Tab. 4). Anonymised individual scores are registered
online; Fig. 1, supplemental Appendix Figs. 2–14.
OCT was considered ‘Appropriate’, in 26 scenarios
(53%); (including stent thrombosis in STEMI, PCI in crit-
ical or distal left main coronary artery (LMCA) lesion,
stent apposition in bioresorbable vascular scaffold (BVS))
(Tab. 4). OCT was considered ‘May be appropriate’, in
18 scenarios (37%). In five scenarios (10%), OCT was
considered ‘Rarely appropriate’; (including late evaluation
strut coverage, post FFR, proximal LMCA, pre rotablation,
in stenosis of graft anastomosis). OCT was rated ‘Appro-
priate’ unanimously for identification of stent thrombosis
mechanism.
Remarks panellists
For ratings other than ‘Appropriate’, additional explanations
were provided.
Houten 2018
Advertisement placed here.
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Table 3 General assumptionsa
1 Operators performing percutaneous revascularisation have appropriate clinical training, experience and have satisfactory outcomes as
assessed by quality assurance monitoring
2 Revascularisation is performed according to international established standards of care [5]
3 The rating panel should rate the appropriateness of the use of OCT on the basis of the clinical scenario presented, including the observed
coronary disease, independently of a judgment about the appropriateness of the coronary angiogram within the given scenario
4 There are no other significant coronary artery stenoses present apart from those described in the clinical scenario
5 Significant coronary stenosis in the clinical scenarios is defined as ≥70% luminal diameter narrowing on angiography or intermediate
angiographic luminal narrowing (40–70%), with an abnormal FFR
6 FFR 0.80 is abnormal and is consistent with downstream ischemia
7 Clinical stent strut malapposition is defined as ≥1–2mm distance between the stent strut and the intimal surface in more than 5% of the
total surface area of the stent
FFR fractional flow reserve, OCT optical coherence tomography
aTo limit inconsistencies in interpretation, these specific assumptions were considered when interpreting the ratings
Fig. 1 OCT appropriate use criteria scores for evaluation of stent thrombosis. On each box, the central mark indicates the median, and the bottom
and top edges of the box indicate the 25th and 75th percentiles, respectively. The whiskers extend to the most extreme data points not considered
outliers, and the outliers are plotted individually as a red dot. The grey dots represent the individual scores of the panellists. The whiskers alongside
the boxplot show the mean and standard deviation (SD). Case 1: Identification of stent thrombosis mechanism in a haemodynamically stable
STEMI patient (Appropriate, Mean= 8; SD ± 0.68). Case 2: Re-evaluation with OCT after STEMI of a hazy non-culprit lesion which was initially
treated conservatively (May be appropriate, Mean= 6; SD ± 1.94). Case 3: Evaluation of mechanism in recurrent STEMI due to stent thrombosis
in the proximal LAD (Appropriate, Mean= 9; SD ± 0.69). (LAD left anterior descending coronary artery, OCT optical coherence tomography,
SD standard deviation, STEMI ST-elevation myocardial infarction)
With regards to OCT-guided PCI of the LMCA, discrep-
ancy existed between proximal (Rarely appropriate) and
distal lesions (Appropriate). In the LMCA, proximal left an-
terior descending coronary artery (LAD) and bypass anas-
tomosis, OCT was considered inferior to FFR and IVUS,
due to insufficient contrast load in the ostium.
Inter-panellist appropriateness scores varied the most for
OCT used to evaluate early or late discontinuation of dual
antiplatelet therapy (DAPT) in relation to strut coverage,
especially in BVS (Tab. 4, Case 6).
Although OCT adjacent to FFR was scored ‘Rarely
appropriate’, assessing characteristics of thin-cap fibroa-
theroma was considered appropriate in a trial setting. Lack
of medical evidence to support the use of OCT in the iden-
tification of early allograft vasculopathy or chronic total
occlusion was mentioned as an explanation for deviating
scores.
Outliers
Outlier testing identified 19 outliers in 12 cases. One out-
lier was caused by a misunderstanding of the clinical sce-
nario. Two outliers could be explained by preference of
other imaging modalities over OCT. Other outliers could
be explained by the lack of evidence or by the lack of
clinical consequences. Because of the low rating sample,
outliers were not discarded.
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Table 4 Summary of clinical scenarios with corresponding ratings
Case Indication (corresponding appendix) Appropriate
use rating
SD
Identification of culprit lesion in acute coronary syndrome (Fig. 1)
1 Identification culprit lesion in NSTEMI with angiographic two significant stenosis and no decisive answer
on which one is the culprit
M (6) ±1.37
2 Identification mechanism STEMI (spasm vs. plaque rupture) after thrombectomy followed by severe spasm M (5) ±2.41
3 Identification culprit lesion in NSTEMI with abnormal ECG and angiographically no evident thrombus or
occlusion
A (7) ±1.77
4 Identification plaque erosion A (7) ±2.02
5 Identification culprit lesion in OHCA with angiographic signs (haziness) A (7) ±2.36
6 Identification culprit lesion in MI with abnormal ECG and angiographically intermediate stenosis M (5) ±1.88
Evaluation of stent thrombosis (supplemental Appendix Fig. 2)
7 Identification of stent thrombosis mechanism in a STEMI patient A (8) ±0.68
8 Re-evaluation with OCT after STEMI of a hazy non-culprit lesion which was initially treated conserva-
tively
M (6) ±1.94
9 Evaluation of mechanism in recurrent STEMI due to stent thrombosis in proximal LAD A (9) ±0.69
Evaluation of strut coverage (supplemental Appendix Fig. 3)
10 Evaluation of strut coverage 4 weeks after initial stent placement in a patient with high bleeding risk (dis-
continuing DAPT)
M (4) ±2.51
11 Evaluation of strut coverage 12 weeks after initial stent placement in a patient with high bleeding risk who
requires surgery (discontinuing DAPT)
R (3) ±1.98
12 Evaluation of BVS after ~1.5 years for discontinuing DAPT M (4) ±2.76
OCT-guided PCI in critical lesions (supplemental Appendix Fig. 4)
13 Guiding in complicated PCI with unknown apposition/position of the stent in the LMCA and post PCI with
possible stent fracture after overexpansion
A (8) ±1.26
14 Guiding in PCI with bifurcation lesion for sizing and stent strategy M (5) ±2.21
15 Guiding in PCI to determine landing zone stent and stent length in angiographically diffuse long lesion M (6) ±2.00
16 OCT next to significant FFR for evaluation stenosis severity R (2) ±1.83
17 OCT next to non-significant FFR for evaluation stenosis severity R (3) ±1.74
OCT guidance in PCI in LMCA (supplemental Appendix Fig. 5)
18 OCT guidance in PCI of the proximal LMCA R (3) ±1.46
19 OCT guidance in PCI of the distal LMCA A (7) ±1.66
Evaluation of stent apposition (supplemental Appendix Fig. 6)
20 Evaluating thrombosis mechanism in extensive stent thrombosis A (9) ±1.03
21 Evaluating stent apposition post PCI in non-complex lesion M (4) ±2.39
22 Evaluating severe calcified lesion for treatment strategy (rotablator?) R (3) ±1.56
23 Evaluating stent apposition after rotablator treatment in complex diffuse long lesion and placement of mul-
tiple stents
A (7) ±1.85
24 Evaluating stent apposition after extensive post-dilatation in an initially undersized stent A (7) ±2.22
Identification of unexplained angiographic abnormalities (supplemental Appendix Fig. 7)
25 Unravel the mechanism for distal occlusion in coronary artery without proximal lesion (local problem or
emboli with other origin?)
A (7) ±2.48
26 Control OCT 5 days after initial angiography in NSTEMI patient which was treated conservatively A (7) ±1.39
27 Evaluation haziness (thrombus) in proximal LAD in STEMI patient with incurable cancer (local problem
or emboli?)
A (7) ±2.17
28 Discrepancy between angiographic finding (intermediate stenosis) and FFR (borderline significant) M (6) ±2.28
29 Evaluation angiographic haziness in transient STEMI A (7) ±1.60
Identification of dissection (supplemental Appendix Fig. 8)
30 Confirmation of SCAD in young patient without classical risk factors for atherosclerotic coronary artery
disease
M (6) ±2.09
31 Identification thrombosis mechanism after thrombosuction resulting in a normal angiography in a patient
with a mechanical valve
A (7) ±2.16
32 Confirmation of SCAD in young patient with classic risk factors for atherosclerotic coronary disease M (6) ±2.24
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Table 4 (Continued)
Case Indication (corresponding appendix) Appropriate
use rating
SD
Stent sizing (supplemental Appendix Fig. 9)
33 Sizing for covered stent with risk on blocking substantial side branch A (7) ±2.55
34 Sizing for stent in hazy angiography with multiple complex lesions M (6) ±1.80
35 Stent sizing in bifurcation lesion (pre PCI) M (6) ±1.94
Evaluation of stent apposition in critical lesions (supplemental Appendix Fig. 10)
36 Control OCT after 2 weeks to evaluate stent apposition in proximal LAD with suspected malapposition
during initial angiography
A (6.5) ±2.22
37 Control OCT for stent apposition in a patient with high bleeding risk and angiographically suspected un-
der-expansion
M (6) ±1.97
38 Evaluating stent apposition in bifurcation lesion (post PCI) A (7) ±1.53
39 Identification of the mechanism behind a distal occlusion in a coronary vessel with multiple mild plaques
proximally (local or emboli of other origin?)
A (7) ±1.35
40 Evaluating stent apposition in a patient with high bleeding risk with the intention to keep the duration of
DAPT treatment as short as possible
A (7) ±1.81
41 Routine use of OCT for evaluation stent apposition in PCI of proximal LAD M (4) ±1.88
In-stent restenosis (supplemental Appendix Fig. 11)
42 OCT identification of the mechanism of ISR in order to guide therapy, i. e. DES vs. DEB after 1st resteno-
sis
M (6) ±1.64
43 OCT identification of the mechanism of ISR in order to guide therapy, i. e. DES vs. DEB after 2nd resteno-
sis
A (7) ±2.35
44 OCT identification of the mechanism of ISR in order to guide therapy, i. e. DES vs. DEB after 3rd resteno-
sis
A (7) ±1.58
Implantation dedicated stent (supplemental Appendix Fig. 12)
45 Evaluation of stent apposition in a BVS A (8) ±2.10
46 Evaluation of stent apposition in a self-expandable stent A (7) ±2.16
OCT in grafts (supplemental Appendix Fig. 13)
47 Detection of early cardiac allograft vasculopathy after heart transplant M (4) ±2.45
48 Detection of stenosis of a CABG anastomosis R (3) ±1.87
OCT in CTO (supplemental Appendix Fig. 14)
49 Evaluation of multiple dissection-like images outside the stent in the sub-intimal path of a previous CTO
during follow-up angiography after CTO recanalisation
A (7) ±2.48
The number in parentheses next to the rating reflects the rounded off mean score for that indication.
A appropriate care, BVS bioresorbable vascular scaffold, CTO chronic total occlusion, DAPT dual antiplatelet therapy, DEB drug-eluting balloon,
DES drug-eluting stent, ECG electrocardiogram, FFR fractional flow reserve, ISR in-stent restenosis, LAD left anterior descending coronary
artery, LMCA left main coronary artery, M may be appropriate care, MI myocardial infarction, NSTEMI non-ST-elevated myocardial infarction,
OCT optical coherence tomography, OHCA out-of-hospital cardiac arrest, PCI percutaneous coronary intervention, SCAD spontaneous coronary
artery dissection, SD standard deviation, STEMI ST-elevated myocardial infarction, R rarely appropriate, RCA right coronary artery
Discussion
The increasing use of OCT contrasts with the scarce liter-
ature on OCT. Appropriate use criteria outline patient sub-
groups where the current medical evidence accompanied
by expert opinion are combined to evaluate whether poten-
tial benefits exceed negative consequences of the treatment
strategy in particular clinical scenarios.
Importantly, this is the first appropriate use criteria docu-
ment on OCT in order to guide clinicians on the reasonable
and appropriate use of OCT, namely preventing either un-
der- or over-utilisation.
Clinical scenarios
The clinical scenarios represented in this document cover
a range of scenarios as encountered in clinical practice, with
the purpose to cover actual and essential clinical situations.
Elaboration on only the noteworthy results of appropri-
ate use criteria, e.g. outliers, unanimous ratings, discrepant
results, will be described because depicting 49 clinical sce-
narios is too comprehensive.
OCT evaluation of stent thrombosis mechanism in
haemodynamically stable STEMI patients was unani-
mously considered ‘Appropriate’, in line with current
literature [6, 7]. Stent thrombosis is a therapeutic challenge
for which treatment guideline recommendations have yet
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to be formulated by international societies. The patho-
physiology of stent thrombosis, however, has been studied
in several recent OCT studies, including PRESTIGE [7],
PESTO [8], and the study by Taniwaki et al. [9]. The un-
derlying mechanisms of stent thrombosis vary depending
on the time elapsed after a PCI, and can be categorised
into two classes; acute or late stent thrombosis. Leading
causes of acute stent thrombosis are under-expansion and
stent malapposition, whereas neo-atherosclerosis, besides
malapposition, has been shown to be a major contributor to
late stent thrombosis [7–9]. The PESTO study revealed that
factors contributing to both categories of stent thrombosis
can be identified with OCT in most cases [8].
Based on these data, it could be recommended to rou-
tinely use OCT to verify stent apposition. This seems espe-
cially appropriate in proximal segments, such as the LMCA
or proximal LAD, where stent thrombosis would have ma-
jor consequences due to the large myocardium at risk. Since
the incidence of stent malapposition is higher after complex
procedures at bifurcations, intravascular imaging is encour-
aged in complex bifurcation procedures in an LMCA or
LAD/diagonal branch lesion [10]. In case of acute PCI with
presence of stent thrombosis and haemodynamic stability,
OCT can easily be performed [11].
In agreement with the literature, the use of OCT guidance
in PCI in a critical or distal LMCA lesion was judged to
be ‘Appropriate’. Critical lesions such as bifurcation lesions
are a complex subgroup encountered in 15–20% of all PCIs.
Compared with simple lesions, they have been associated
with longer procedures and lower procedural success rates,
i. e. less optimal angiographic and clinical outcomes [12,
13].
LMCA bifurcation lesions are an increasingly common
site of complex stent implantation. Using OCT, Burzotta
et al. were able to evaluate LMCA bifurcation lesions with
a high degree of accuracy [14].
This approach is endorsed by the European Bifurcation
Club, which recommends OCT guidance as well as IVUS
guidance for the management of LMCA bifurcations [15].
The multicentre, randomised OPUS-CLASS study com-
pared OCT versus IVUS in measuring of the lumen and
in guidance in PCI. This study showed that OCT allows
accurate and reproducible measurements of the coronary
dimensions in day-to-day clinical practice [16], and is con-
siderably more sensitive than IVUS in the detection of var-
ious indicators of suboptimal post-PCI lesion morphology
(e.g. intra-stent tissue protrusion, incomplete stent apposi-
tion, stent edge dissection, and intra-stent thrombus) [17,
18].
In the current study, evaluating stent apposition in biore-
sorbable vascular scaffolds (BVS) was deemed ‘Appropri-
ate’. The implant of BVS stents is associated with a higher
risk of subacute stent thrombosis than the implant of drug-
eluting stents (DES) [19]. There is a 3-fold higher incidence
of acute and subacute BVS thrombosis, usually clustered
within 30 days, than DES thrombosis [20–22]. The under-
lying mechanisms of stent thrombosis in BVS and DES are
similar and include incomplete lesion coverage and under-
expansion and malapposition of the stent [23]. The higher
risk of stent thrombosis associated with BVS is probably
due to thicker struts, which makes BVS less tolerant for
suboptimal implantation.
In divergent clinical scenarios in which scientific evi-
dence for the use of OCT is lacking, the use of OCT was
considered ‘May be Appropriate’. The biggest dispersion
in ratings with regards to the use of OCT was related to
the evaluation of strut coverage of BVS. Neo-intimal cov-
erage and endothelialisation after BVS implantation or its
clinical time course has not been fully elucidated. The un-
certainty which percentage of coverage is needed to safely
stop DAPT may explain the experts’ doubts on the useful-
ness of OCT in this scenario [22].
The AIDA study showed that definite or probable device
thrombosis occurs more often in BVS than in DES [22].
As a consequence, the Netherlands Society of Cardiology
(NVVC) has adopted a consensus to maintain DAPT for
3 years if the Absorb BVS has been used, after which time
the scaffold will most likely be completely absorbed.
OCT guidance could be of use in PCI procedural plan-
ning, for instance in stent sizing. In the ILUMIEN I study,
OCT guidance changed the planned treatment strategy in
57% of cases. Remarkably, in 31% of cases, OCT led to
stenting with a smaller diameter stent size [24]. Addition-
ally, OCT led to changes in selection of stent length in 68%.
In the setting of multiple complex lesions or a bifurcation
lesion, the expert panel considered OCT guidance as ‘May
be appropriate’. In contrast, in non-complex lesions angiog-
raphy alone was considered sufficient for stent sizing, and
the use of OCT was deemed ‘Rarely appropriate’.
Additionally, OCT-guided evaluation of late strut cover-
age in order to discontinue DAPT in patients with a high
risk for bleeding was also considered ‘Rarely appropri-
ate’. The panellists argued that with third generation DES
and with sufficient stent apposition in the index procedure,
DAPT could be stopped. The current literature endorses this
point of view, and suggests that after implantation of new-
generation DES, treatment with DAPT for 3–6 months may
suffice to prevent stent thrombosis [25].
Another clinical scenario in which the use of OCT was
considered ‘Rarely appropriate’ was the use of OCT ad-
jacent to FFR. If the severity of the stenosis is uncertain,
current practice guidelines propose the use of FFR. Nev-
ertheless, the measurement of FFR may be unreliable for
multiple stenoses, e.g. distal flow-limiting stenosis or col-
lateral flow. Thus, minimal luminal area on OCT may be
considered in these cases as an alternative. OCT is a suitable
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technique in such cases, except for ostial LMCA lesions
[14]. Moreover, the DOCTORS study found that OCT-
guided PCI modified the procedural strategy chosen by the
physician in 50% of cases. OCT-guided PCI was associated
with a post-procedural FFR >0.90 in 82.5% of patients, ver-
sus 64.2% of patients who underwent angiography-guided
revascularisation [26].
OCT assessment of the LMCA is feasible and safe, and
compared with IVUS more sensitive in detecting malappo-
sition and edge dissection, and equivalent in the assessment
of lumen and stent dimensions. However, direct compar-
isons with IVUS reveal that OCT achieves imaging com-
pleteness less often [27]. As a result, the use of OCT in
the proximal LMCA was considered ‘Rarely appropriate’
by the panellists.
Interpretation
The appropriate use criteria procedure is intended to be
transparent for readers. Accordingly, the panellist’s numer-
ical scores can be found online; Appendix Fig. 1, supple-
mental Appendix Figs. 2–14.
Because the division of the appropriateness scores in
3 categories may be arbitrary, scores should actually be
viewed as a continuum. Nevertheless, the categories are pro-
posed for clinical application. The array in clinical opinions
for specific scenarios has been acknowledged. Thus the cri-
teria can inform procedural use of OCT but physician judge-
ment is required for patient-specific decisions. Additionally,
this clinical scenario series is intended to be thorough, with-
out being extensive. Therefore, some encountered clinical
situations may not fit exactly into any of the scenarios pre-
sented, making certain procedures that are rated ‘Rarely
appropriate’ admissible in particular settings. It is advised
to clearly document these exemptions.
We envision that the interpretation and application of
these criteria will provide insights into the way of care and
will help to inform future guidelines for the use of OCT.
Limitations
The validity of the observations may be influenced by the
fact that 1) authors of the clinical scenarios also partici-
pated in the consensus panel and 2) there was no explicit
balance in the panel between non-experts and experts since
members of the Dutch Working Group on Interventional
Cardiology participating in the expert panel most probably
were more engaged and experienced in the OCT technol-
ogy.
Although appropriate use of IVUS was not assessed rou-
tinely for the different clinical scenarios, it was taken in
consideration during rating of the clinical scenarios. While
these appropriate use criteria ratings reflect the current ev-
idence accompanied by expert consensus, inevitably more
research is needed to further identify not only when to use
OCT but also when to choose OCT over other imaging
modalities.
Conclusion
In summary, this document presents, for the first time, side-
by-side ratings by clinical experts of OCT in 49 clinical sce-
narios. OCT was considered ‘Appropriate’ when applied for
guidance in PCI of the LMCA and the proximal LAD, eval-
uation of stent thrombosis in STEMI patients or apposition
of BVS. OCT was considered as ‘May be appropriate’ when
applied for evaluation of routine apposition or stent sizing.
The use of OCT next to FFR was considered ‘Rarely ap-
propriate’, unless applied in a trial setting. Additionally, the
use of OCT for evaluation of strut coverage, bypass anasto-
moses or an ostium of the LMCA was considered ‘Rarely
appropriate’.
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